Based upon preclinical work demonstrating synergistic activity in CRC between MEK and MET inhibitors [59], the MErCuRIC1 study is investigating the combination of the MEK inhibitor PD-0325901 and crizotinib in patients with KRAS mutant, or KRAS WT, MET-amplified CRC (Table 1). This evidence concerns the gene KRAS and colorectal carcinoma.